Deep Intelligence Across Industries

Company Headquarters: Washington, D.C., US Founded: 1969 Workforce: ~71,000 Company Working: Danaher designs, manufactures, and markets professional, medical, industrial, and commercial products and services all over the world. The company has five business segments, namely, life sciences, diagnostics, dental, water quality, and product identification. Its life sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. It also offers dental implant systems, high-precision individualized prosthetics, and CAD/CAM systems under the brand name Nobel Biocare. The company operates through more than 20 subsidiaries in the global market.

Company Headquarters: Basel, Switzerland Founded: 1954 Workforce: 5,954 Company Working: Institut Straumann AG (Straumann) is a global leader in the field of implant, restorative, and regenerative dentistry. The company develops and manufactures dental implants, instruments, prosthetics, and dental biomaterials for use in tooth replacement and restoration. Straumann offers a diverse range of products and solutions for both conventional treatment and digital workflows, including guided surgery, intra-oral scanning, and CAD/CAM restorations. As of March 2017, approximately 17 million Straumann implants have been placed worldwide. Straumann has various international brands including Anthogyr, Medentika, Neodent, ClearCorrect, and Dental Wing. The company sells its products through a well-developed network of distribution subsidiaries and partners.

Dentsply Sirona describes itself as the world's largest diversified manufacturer of professional dental products and technologies. Its portfolio runs from high-ticket connected equipment (CEREC chairside CAD/CAM, Primescan intraoral scanners, Orthophos and Axeos imaging, treatment centres) to recurring consumables (endodontics, restoratives, preventive products, anaesthetics), dental implants and digital orthodontics (SureSmile). It also owns a non-dental continence-care franchise, Wellspect (LoFric, Navina). The company is in the second year of a turnaround. Net sales have fallen from USD 4.25bn (FY2021) to USD 3.68bn (FY2025). Cumulative goodwill and intangible impairments exceed USD 2bn since 2022. A failed direct-to-consumer aligner venture (Byte) was suspended in late 2024. CEO Dan Scavilla's 24-month "Return-to-Growth Action Plan" (November 2025) rebuilds dealer relationships, redirects about USD 120m a year into innovation and clinical education, eliminated the dividend (February 2026), and prioritises deleveraging. At about 6x forward adjusted EPS, the equity is priced as a distressed turnaround of a franchise that still leads its category. --- ### Company's own description (FY2025 10-K / annual report) The company describes itself as developing, manufacturing and marketing "a comprehensive solutions offering, including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands." Its vision covers improving oral health and continence care globally. Its products aim to "provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care" (2026 press-release boilerplate). ### Business model and revenue model | Revenue type | Approximate weight | Notes | |---|---|---| | Capital equipment and technology (CAD/CAM, scanners, imaging, treatment centres, instruments) | ~28% of FY2025 sales (CTS segment) | Cyclical and financing-sensitive; sold mainly through dealers | | Consumables (endodontic, restorative, preventive, anaesthetic, lab materials) | ~40% (EDS segment) | Recurring and replenishment-driven; the highest segment margins | | Implants, prosthetics, aligners, digital dentures, digital services | ~23% (OIS segment) | Procedure-driven and partly sold direct; includes DS Core cloud platform services | | Continence care medical devices (Wellspect) | ~9% | Recurring patient-use consumables, sold through medical distributors and direct to patients | | Software / subscription / service | Not separately disclosed | DS Core cloud, software licences and service contracts are embedded in CTS and OIS. No subscription revenue line is disclosed | Dentsply Sirona is overwhelmingly a product company. Revenue is recognised mainly when goods ship to distributors or end customers. The mix is best described as follows: ### Value-chain position and channels The company is a vertically integrated designer and manufacturer (R&D, manufacturing and brand ownership). Per the FY2025 10-K, about two-thirds of dental consumable and technology/equipment sales go through third-party distributors. Endodontic instruments and materials, implants and orthodontic aligners and appliances are often sold directly to dental labs or professionals. Continence-care products are sold primarily to medical-supply distributors, with the remainder sold direct to patients and providers. **Customer concentration (FY2025 10-K):** - Henry Schein accounted for 13% of FY2025 net sales, down from 14% in FY2023. - Patterson Companies accounted for 11% of accounts receivable at year-end 2025. - No customer exceeded 10% in FY2024. ### Customer types and end-markets **Customers:** general dental practitioners; specialists (endodontists, orthodontists, oral surgeons, periodontists, prosthodontists); dental laboratories; dental service organisations (DSOs, for example PDS Health); dental schools; hospitals; and urology/gastro patients and providers (Wellspect). **End-markets:** global professional dental equipment and consumables, dental implants and biomaterials, clear aligners and orthodontics, dental lab/CAD-CAM, and intermittent catheterisation and transanal irrigation. ### Independent characterisation Dentsply Sirona is a scale-advantaged but structurally challenged incumbent. It has the broadest dental portfolio in the industry and an installed base of CEREC/Primescan workflows. However, it has lost share in digital (intraoral scanners and chairside CAD/CAM) to faster-moving rivals (3Shape, Medit, Align iTero) on price and openness. It has also damaged dealer relationships through a 2024 ERP migration and channel-inventory practices, and destroyed capital on Byte. The consumables franchise (EDS) is the profit engine. Its segment adjusted operating income was USD 403m in 9M FY2025, versus only USD 29m from CTS over the same period. The equipment business is near break-even at the segment level. The investment case rests on whether the 2026 dealer-network rebuild and the R&D step-up (to at least 5% of sales) can stabilise CTS and OIS before balance-sheet covenants tighten in 2027.

Company Headquarters: California, US Founded: 1997 Workforce: ~13,685+ Company Working: Align Technology, Inc. (Align Technology) is a company manufacturing medical devices. The company is into designing, manufacturing, and marketing of Invisalign system, intra-oral scanners and CAD/CAM digital services used in dentistry, orthodontics, and dental records storage. Its product portfolio comprises Invisalign clear aligners and iTero intraoral scanners and services for orthodontics, restorative, and aesthetic dentistry. Its products are primarily used for the treatment of malocclusion or the misalignment of teeth. The company also sells other ancillary products for the iTero scanner, such as disposable sleeves for the wand. Align Technology has a business presence across North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. It operates through the clear aligner and scanner and services segments. The clear aligner segment consists of Invisalign full, teen and assists products, and Vivera retainers along with training and ancillary products for treating malocclusion. The scanner and services segment comprise of intraoral scanning systems and additional services available with intraoral scanners that provide digital alternatives to traditional cast models. The Invisalign system is offered in more than 90 countries worldwide by Invisalign-trained doctors to their adult and teenage patients. Its Invisalign system has treated more than 7.2 million patients including 1.7 million teenagers.

Company Headquarters: Nishinomiya, Hyōgo Prefecture, Japan Founded: 1951 Workforce: ~2,930 Company Working: FURUNO Electric Co., Ltd is engaged in the manufacturing and sales of marine and industrial electronic equipment. The company operates through three business segments, namely marine, industrial, and wireless LAN/ handy terminal. The marine segment consists of navigation instruments, sonar systems, fishing instruments and radio communications equipment. The industrial segment consists of global positioning system (GPS) equipment, medical equipment, intelligent transport system (ITS) equipment and aviation devices. The others segment is consists of electronic equipment for aircraft, wireless handy terminals, and wireless local area network.

Company Headquarters: Greenford, London, UK Founded: 1920 Workforce: ~4,100 Company Working: Ultra Electronics offers a wide range of specialist capabilities, generating highly-differentiated solutions and products in the security & cyber, defense & aerospace, transport, and energy markets. It provides support to its customers through the design, delivery, and support phases of a program. It focuses on a high degree of operational autonomy to provide quality products and aftersales support to customers and partners. Operationally, the group is organized into three major divisions, namely aerospace & infrastructure, communications & security, and maritime & land. The firm provides sonar systems under its maritime & land segment.

SAP SE is the world's largest vendor of enterprise application software and the only Fortune-50-scale technology company headquartered in Europe. It sits at the transactional core of the global economy: its ERP systems record and execute the financial, procurement, supply-chain, manufacturing and human-capital processes of a large share of the world's biggest enterprises. The company is roughly four-fifths of the way through a decade-long conversion from a perpetual-licence, on-premise vendor to a cloud subscription business — cloud revenue reached €21.02bn in FY2025, 57% of total revenue, against €8.70bn and 32% in FY2021. That transition is now producing the operating leverage the equity story always promised: FY2025 non-IFRS operating margin of 28.3% and free cash flow of €8.24bn, nearly double the prior year. The strategic question for the next cycle is whether SAP can convert its unmatched process-and-data estate into a defensible position in agentic enterprise AI before hyperscalers, Oracle, Salesforce and AI-native challengers commoditize the application layer above it. --- ### What SAP does SAP develops, licenses, hosts, operates and supports enterprise application software, together with the data and AI platform layer beneath it and the professional services required to implement and run it. Its core product is enterprise resource planning (ERP) software — the system of record that governs a company's general ledger, financial close, procurement, inventory, production planning, order-to-cash, and workforce administration. Around that core SAP has assembled adjacent "line-of-business" suites for spend management (Ariba, Concur, Fieldglass), supply chain (Integrated Business Planning, Business Network), human capital (SuccessFactors), customer experience (Commerce, Sales, Service, Customer Data Cloud), and business transformation management (Signavio, LeanIX, WalkMe). In SAP's own framing from the FY2025 disclosures, the company describes itself as "a global leader in enterprise applications and business AI" that "stands at the nexus of business and technology," uniting "business-critical operations spanning finance, procurement, HR, supply chain, and customer experience." ### Independent characterization The more analytically useful description is that SAP operates three economically distinct businesses inside one P&L: 1. **A declining but extraordinarily profitable maintenance annuity.** Software support revenue of €10,525m in FY2025 (down 7% from €11,290m in FY2024) carries gross margins near 89%. This is the cash engine funding the transition. SAP has explicitly guided that the constant-currency decline rate of software support revenue will *accelerate* in coming years as customers migrate. 2. **A rapidly compounding cloud subscription business.** Cloud revenue of €21,023m in FY2025 (+23% reported, +26% constant currency), of which Cloud ERP Suite is €18,119m (+28%). Cloud gross margin reached 74.2% IFRS / 75.0% non-IFRS in FY2025, up 1.4pp / 1.7pp year over year — evidence that scale economics in SAP's hyperscaler-hosted delivery model are real. 3. **A low-margin services arm** (€4,262m, down 2% in FY2025) that exists largely to seed and de-risk cloud deals rather than to generate profit in its own right. SAP deliberately channels most implementation work to partners. ### Revenue model and mix | Revenue line (€m, IFRS) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |---|---|---|---|---|---| | Cloud revenue | 8701 | 11426 | 13664 | 17141 | 21023 | | Thereof Cloud ERP Suite | 0 | 8209 | 10626 | 14165 | 18119 | | Thereof Extension Suite | 0 | 0 | 2290 | 2436 | 2559 | | Thereof IaaS | 0 | 0 | 748 | 540 | 345 | | Software licenses | 0 | 0 | 1764 | 1399 | 990 | | Software support | 0 | 0 | 11496 | 11290 | 10525 | | Cloud and software revenue | 23361 | 25391 | 26924 | 29830 | 32538 | | Services revenue | 3592 | 4128 | 4283 | 4346 | 4262 | | Total revenue | 26953 | 29520 | 31207 | 34176 | 36800 | | Share of more predictable revenue (%) | 75 | 79 | 81 | 83 | 86 | *Zeros indicate line items not separately disclosed on a comparable continuing-operations basis in the FY2025 Five-Year Summary or FY2025 income statement; Cloud ERP Suite was first disclosed for FY2022. Source: SAP Integrated Report 2025, Consolidated Income Statements and Five-Year Summary.* The commercial model has four pricing constructs: (i) subscription per user/per module/per consumption metric for cloud; (ii) legacy perpetual licence plus ~19–22% annual maintenance for on-premise; (iii) time-based on-premise licences (recognized at a point in time, with associated support over time — combined with cloud into SAP's "subscription revenue" measure of €21,328m in FY2025, up 22%); and (iv) time-and-materials or fixed-fee professional services. Cross-cutting bundles — RISE with SAP (managed migration of existing ERP estates to private cloud) and GROW with SAP (greenfield public-cloud ERP for mid-market and new logos) — package software, infrastructure, tooling and services into a single contract. ### Value chain position and customers SAP occupies the application layer. It does not own its own hyperscale infrastructure at scale — it runs the substantial majority of its cloud estate on Amazon Web Services, Microsoft Azure and Google Cloud, supplemented by SAP-operated data centres for sovereign and regulated workloads (Delos Cloud in Germany, SAP NS2 in the United States, and the EU AI Cloud launched November 27, 2025). Downstream, implementation and change management are performed overwhelmingly by a partner ecosystem — Accenture, Deloitte, Capgemini, Infosys, TCS, Wipro, IBM, PwC, KPMG, EY, Tech Mahindra, Birlasoft and thousands of regional partners. Customer types skew heavily toward large enterprises and public-sector bodies. FY2025 and H1 2026 disclosed wins illustrate the profile: adidas, Bertelsmann, BioNTech, Daimler Truck, Deloitte, Électricité de France, H&M Group, HM Revenue & Customs, Jabil, Kirin Holdings, Nokia, Pirelli, RTX, Toyota, Weir Group, ACCIONA, Airbus, Electrolux, Eli Lilly, Gilead Sciences, Hindustan Zinc, Ørsted, Shell, Sun Pharma, Vonovia, Lockheed Martin, Rolls-Royce SMR, Mondelez International, Robert Bosch, Schaeffler, Zalando, Deutsche Bundesbank and Bank of Italy. Mid-market penetration runs through GROW with SAP and partner-led motions. End-markets served are effectively every asset-heavy and process-heavy industry: discrete and process manufacturing, automotive, aerospace and defence, chemicals, pharmaceuticals and life sciences, consumer products, retail, wholesale distribution, utilities and energy, oil and gas, mining, banking and insurance, telecommunications, transportation and logistics, professional services, healthcare, higher education and public sector.

Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:8.0pt; mso-para-margin-left:0in; line-height:107%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Roboto Condensed"; mso-ascii-font-family:"Roboto Condensed"; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:"Roboto Condensed"; mso-hansi-theme-font:minor-latin;} Company Headquarters: Newcastle Upon Tyne, UK Founded: 1981 Workforce: ~ 12,755 Company Working: The Sage Group (Sage) is a technology solutions and services company which offers accounting solutions, financials, enterprise management, people, Sage business cloud people, and Sage Intacct— a solution specifically for CFOs to provide access to financial reports and integrated management across business entities. The company targets professional users, typically accountants or bookkeepers, who require high functionality and technical efficiency to gain insights into their businesses. Sage offers solutions to small and medium-sized businesses in the manufacturing and education sectors according to their business needs. The company serves over 3 million customers across 23 countries in Europe, Africa, Australia, Asia, and the Americas.

Starbucks is the world's largest specialty coffee company and, by a wide margin, the dominant global operator of branded coffeehouses. It vertically integrates green-coffee sourcing, proprietary roasting and a 41,000-store retail estate spanning 89 markets, monetised through three channels: directly operated coffeehouses, a licensed store network run by regional partners, and a consumer-packaged-goods and foodservice franchise operated principally through the Global Coffee Alliance with Nestlé. The economic engine is North America, which generated 74% of fiscal 2025 revenue. Following two years of comparable-sales erosion, the company is executing a comprehensive operational reset — "Back to Starbucks" — under chairman and chief executive Brian Niccol, appointed September 2024. That reset has produced four consecutive quarters of comparable-sales growth through Q3 fiscal 2026 and two consecutive quarters of margin expansion, alongside a decisive shift in capital structure: the April 2026 divestiture of a controlling interest in Starbucks China converts the company's second-largest market to an asset-light licensing relationship. --- ### The company's own characterisation In its fiscal 2025 Annual Report on Form 10-K, Starbucks describes itself as the premier roaster, marketer and retailer of specialty coffee worldwide, operating in 89 markets. It purchases and roasts high-quality coffees, which it sells alongside handcrafted coffee, tea and other beverages together with food through company-operated stores (which the company calls "coffeehouses"). It also sells coffee and tea products and licenses its trademarks through other channels — licensed stores, and grocery and foodservice via the Global Coffee Alliance with Nestlé S.A. Beyond the flagship Starbucks Coffee brand, the company markets goods and services under the Teavana, Ethos and Starbucks Reserve marks. The company states that its primary objective is to sustain Starbucks' standing as one of the most recognised and respected brands globally, and that continuous investment in brand and operations will deliver long-term revenue and income growth. That includes expanding the global store base in both mature markets such as the United States and higher-growth markets, and optimising the mix of company-operated and licensed stores. It emphasises beverage, equipment, process and technology innovation, including its digital platform. ### Independent characterisation Starbucks is best understood as three economically distinct businesses sharing one brand and one supply chain: **(a) A capital-intensive, high-fixed-cost retail operator.** Company-operated stores generated 82.7% of fiscal 2025 net revenue ($30,744.8m of $37,184.4m). This business carries the full weight of store labour, occupancy and depreciation. In fiscal 2025 store operating expenses reached 55.5% of company-operated store revenue, up from 51.4% in fiscal 2024 — a 410-basis-point deterioration that is the single most important line item in understanding the fiscal 2025 profit collapse. Almost all of the 21,514 company-operated stores at fiscal 2025 year-end were leased, which is why operating lease liabilities of $10.5bn sit alongside $16.1bn of financial debt on the balance sheet. **(b) A royalty-and-wholesale licensing business.** Licensed stores produced 11.7% of fiscal 2025 revenue ($4,350.4m). Under this model Starbucks earns a margin on branded product and equipment sold to the licensee plus a royalty on the licensee's retail sales; the licensee bears operating costs and capital expenditure. Licensed stores carry lower gross margin but structurally higher operating margin than company-operated stores. This is the model Starbucks is now deliberately migrating toward: the April 2026 conversion of roughly 7,991 China company-operated stores to licensed status was the largest single such shift in the company's history. **(c) A consumer-packaged-goods and foodservice franchise.** "Other" revenue — 5.6% of fiscal 2025 revenue ($2,089.2m) — is recorded largely in Channel Development and comprises packaged coffee, tea and ready-to-drink sales outside the store estate plus Nestlé royalties. This is by far the highest-margin part of the enterprise: Channel Development operating margin was 47.3% in fiscal 2025 and 52.1% in Q3 fiscal 2026. It is also the least capital-intensive, since Nestlé controls distribution and, in some cases, roasting and packaging of Starbucks packaged products outside Starbucks stores. ### Revenue model composition | Revenue stream (USD M) | FY2023 | FY2024 | FY2025 | |---|---|---|---| | Company-operated stores | 29552 | 29765.9 | 30744.8 | | Licensed stores | 4517 | 4505.1 | 4350.4 | | Other (CPG, foodservice, royalties) | 1906 | 1905.2 | 2089.2 | | Total net revenues | 35975.6 | 36176.2 | 37184.4 | | Consolidated revenue by product type (USD M) | FY2023 | FY2024 | FY2025 | |---|---|---|---| | Beverage | 21684.8 | 21883.9 | 22539.9 | | Food | 6585.1 | 6749.2 | 7049.9 | | Other | 7705.7 | 7543.1 | 7594.6 | | Total | 35975.6 | 36176.2 | 37184.4 | *(FY2024 and FY2025 from the Q4 FY2025 earnings release, 29 October 2025; FY2023 components derived from the FY2023 Form 10-K and shown as approximate.)* *(FY2025 Form 10-K, segment note.)* Within company-operated stores specifically, the retail sales mix in fiscal 2025 was 73% beverages, 23% food and 4% other, versus 74%/23%/3% in fiscal 2024 and 74%/22%/4% in fiscal 2023 (FY2025 Form 10-K). The food attach rate has been a deliberate management lever; Q3 fiscal 2026 ticket growth of 3.5% in North America was attributed in part to food attach and beverage modification. ### Value chain position Starbucks occupies an unusually long stretch of the coffee value chain for a retailer. It controls substantially all green-coffee purchasing, roasting, packaging and global distribution for its own operations, operates ten farmer support centres (including one in Yunnan Province, China) staffed with agronomists, and owns most of its roasting plants while leasing the majority of warehousing and distribution facilities. Upstream, it does not own coffee farms at scale; it purchases from producers, trading companies and exporters using fixed-price and price-to-be-fixed commitments, hedged with forwards, futures and collars. Downstream in the CPG channel it has ceded distribution to Nestlé in exchange for an upfront payment and an ongoing royalty stream — an asset-light structure that materially improves returns but reduces control. ### Customer types and end-markets **Retail consumers:** the overwhelming majority of revenue, transacting in-store, via drive-thru, mobile order-and-pay, and third-party delivery. Starbucks Rewards had 34.2m 90-day-active U.S. members at fiscal 2025 year-end and 35.5m at January 2026, and the programme drove nearly 60% of U.S. company-operated revenue in fiscal 2025 (2026 Investor Day, 29 January 2026). **Licensee operators:** regional master licensees and franchisees who buy product, equipment and supplies from Starbucks and remit royalties. Concentration among a small number of large regional licensees is explicitly flagged as a risk factor. **Grocery, club and convenience retail:** served through Nestlé under the Global Coffee Alliance. **Foodservice accounts:** offices, hotels, universities, hospitals, airlines and airports. **Joint-venture partners:** the North American Coffee Partnership with PepsiCo for ready-to-drink, and from April 2026 the Boyu Capital joint venture in China in which Starbucks retains 40%. No single customer accounts for 10% or more of revenues (FY2025 Form 10-K).

Eurofins Scientific is the world's largest independent bioanalytical testing network. Its brand line is "Testing for Life". From a single Nantes laboratory that commercialised the SNIF-NMR isotopic method for authenticating wine and juice, it has grown into a decentralised federation of more than 1,000 companies. These test food, feed, water, soil, air, pharmaceuticals, medical devices, cosmetics, consumer goods, advanced materials and human clinical samples. FY2025 revenue was €7,296m and adjusted EBITDA was €1,641m (a 22.5% margin). Through Eurofins EAG Laboratories, MASER Engineering, Eurofins FQL and Chip Test Solutions, the group runs one of the largest independent materials-characterisation, failure-analysis, reliability and automated test equipment (ATE) networks serving semiconductor fabs, fabless designers, OSATs and equipment makers. That is why the group appears in assessments of the semiconductor quality and certification services market. Two transactions are sharpening the portfolio around life-science testing: the 2026 sale of the Electrical & Electronic Testing business (MET Labs) to UL Solutions for €575m, and the US$400m purchase of Element Materials Technology's North American Life Sciences Testing Services. Materials and semiconductor testing stay in the group. --- ### What the company does Eurofins provides analytical testing and related laboratory services. Its own description is a network that "offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity" of a wide range of products. It also provides "innovative clinical diagnostic testing services and in-vitro diagnostic products". Management calls Eurofins a global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience. It describes the group as one of the market leaders in certain genomics services, clinical-study support and biopharma contract development and manufacturing (CDMO). Management adds that it has a fast-developing presence in specialised and molecular clinical diagnostics and in in-vitro diagnostic (IVD) products. ### Business model The model rests on four design choices: 1. **Decentralised, entrepreneurial structure.** More than 1,000 legal entities run with local profit-and-loss accountability under empowered leaders. Group-wide functions (IT, finance, real estate, procurement) are centralised. 2. **Hub-and-spoke laboratory network.** Large, highly automated hub laboratories, increasingly in owned campuses, are fed by spoke laboratories, sample-collection points and logistics. This lowers unit costs and shortens turnaround times. The group's five-year investment programme (2023–2027) is built around completing this network and digitalising it end to end. 3. **Proprietary digital stack.** In-house laboratory information management systems (including the commercial LIMS, ComLIMS), customer portals and automation. Management treats this as a core competitive moat. 4. **Capital-intensive build-out.** About 345 start-up laboratories and 141 blood collection points (BCPs) have been launched since 2000, alongside a steady pace of bolt-on acquisitions (40 business combinations in FY2025; 17 in H1 2026). Owned real estate is increasing, at 905,000 m² of the 1,878,000 m² total net floor area at end-2025. ### Revenue model Eurofins earns almost all of its revenue from services. The group reports revenue by service-line type: **Sample-based revenue:** (fee per test or per sample). This is the core of the model, covering routine food, environment, product testing and clinical diagnostics. **Study-based revenue:** (contract studies, mainly agroscience, discovery and preclinical). **FTE-based revenue:** (Professional Scientific Services, where Eurofins scientists work at client sites, mainly in BioPharma). **Product-based revenue:** (IVD kits, reagents, assays), which is a small share. For FY2024, data-provider extracts of the annual report break this down as about €5.81bn sample-based, €521m study-based, €478m FTE-based and €139m product-based. Product sales are therefore about 2% of revenue. Subscription and licensing revenue is not material. ### Value-chain position and customers Eurofins is an outsourced quality, safety and compliance partner. Its customers include: - food and beverage manufacturers, retailers and ingredient suppliers; - environmental consultants, utilities, industrial operators and regulators; - pharmaceutical, biotech and medical-device companies at every stage from discovery to commercial batch release; - agrochemical and seed companies; - hospitals, physicians, payers and public screening programmes; - consumer-goods brands and retailers; and - in Consumer & Technology Products Testing, semiconductor and electronics companies, aerospace and defence contractors and advanced-materials producers. The group has stated that its exposure to China is less than 20% of consolidated revenue. Peers cited in short-seller commentary have between 40% and 50%. ### End markets served (business lines) | Business line | FY2025 revenue (€m) | Share of FY2025 revenue | Main activities | |---|---|---|---| | Life | 3,043 | 41.7% | Food & Feed Testing, Environment Testing (including PFAS), Agroscience | | BioPharma | 2,062 | 28.3% | BioPharma Product Testing, Discovery & Genomics, CDMO, BioPharma Services, Medical Device Services, central-lab and bioanalysis | | Diagnostic Services & Products | 1,496 | 20.5% | Routine and specialty clinical diagnostics (including the former SYNLAB Spain), transplant and infectious-disease testing (Viracor), IVD products | | Consumer & Technology Products Testing | 695 | 9.5% | Consumer Product Testing (softlines, hardlines, cosmetics, toys), Materials & Engineering Sciences (EAG, MASER, FQL), Electrical & Electronic Testing (MET Labs, divested October 2026) | **Life:** FY2025 revenue (€m): 3,043; Share of FY2025 revenue: 41.7%; Main activities: Food & Feed Testing, Environment Testing (including PFAS), Agroscience **BioPharma:** FY2025 revenue (€m): 2,062; Share of FY2025 revenue: 28.3%; Main activities: BioPharma Product Testing, Discovery & Genomics, CDMO, BioPharma Services, Medical Device Services, central-lab and bioanalysis **Diagnostic Services & Products:** FY2025 revenue (€m): 1,496; Share of FY2025 revenue: 20.5%; Main activities: Routine and specialty clinical diagnostics (including the former SYNLAB Spain), transplant and infectious-disease testing (Viracor), IVD products **Consumer & Technology Products Testing:** FY2025 revenue (€m): 695; Share of FY2025 revenue: 9.5%; Main activities: Consumer Product Testing (softlines, hardlines, cosmetics, toys), Materials & Engineering Sciences (EAG, MASER, FQL), Electrical & Electronic Testing (MET Labs, divested October 2026) ### Independent characterisation Eurofins is best understood as a scale testing platform that sits between the traditional testing, inspection and certification (TIC) groups (SGS, Bureau Veritas, Intertek) and the life-science contract research organisations (Charles River, Labcorp). Its revenue per employee, scientific intensity and BioPharma weighting (more than 30% of activity, according to management) separate it from inspection-heavy TIC peers. Its routine food, environmental and clinical testing gives it a more defensive, regulation-driven revenue base than the CROs. The semiconductor and materials franchise is small within the group (well under 10% of revenue) but technically differentiated. EAG describes itself as the world-leading independent materials-characterisation and engineering resource for semiconductor testing, with techniques such as SIMS, TEM/FIB and plasma FIB, failure analysis, reliability qualification and production ATE.

Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin-top:0cm; mso-para-margin-right:0cm; mso-para-margin-bottom:8.0pt; mso-para-margin-left:0cm; line-height:107%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Roboto Condensed"; mso-ascii-font-family:"Roboto Condensed"; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:"Roboto Condensed"; mso-hansi-theme-font:minor-latin; mso-ansi-language:EN-US; mso-fareast-language:EN-US;} Company Headquarters: Leidschendam, Netherlands Founded: 1962 Workforce: ~10,265 Company Working: Fugro is one of the leading providers of geo-intelligence and asset integrity solutions for construction, natural resources, and infrastructure. It provides information and technical data required to design, construct, and maintain structures. The company operates through three business segments—marine, land, and geoscience. The marine segment includes marine site characterization and marine asset integrity. Fugro caters to industries such as oil & gas, power, building and infrastructure, and mining. The company has 40 laboratories, 16 research & development centers, and 32 consulting services with a presence in over 65 countries. William Lettis & Associates, Inc., Fugro GeoServices Limited, Fugro Survey BV, and Maps Geosystems are some of the subsidiaries of the company.

Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin-top:0cm; mso-para-margin-right:0cm; mso-para-margin-bottom:8.0pt; mso-para-margin-left:0cm; line-height:107%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Roboto Condensed"; mso-ascii-font-family:"Roboto Condensed"; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:"Roboto Condensed"; mso-hansi-theme-font:minor-latin; mso-ansi-language:EN-US; mso-fareast-language:EN-US;} Company Headquarters: Kirkegardsveien, Kongsberg, Norway Founded: 1916 Workforce: ~6,900 Company Working: Kongsberg Maritime is a subsidiary of Kongsberg Gruppen—a global technology company providing systems and solutions to various sectors such as aerospace, defense, offshore oil & gas, and utilities. Kongsberg Maritime manufactures systems for positioning, surveying, and navigating offshore installations. As part of its marine navigation system, the company provides AUVs, radars, chart plotters, sonar systems, display systems, navigation sensors, and gyrocompasses, among others. Kongsberg Maritime has production, research and development, and personalization and data centers in Norway, Australia, the US, Germany, Canada, France, Sweden, Brazil, and the UK.

Company Headquarters: Massachusetts, US Founded: 1947 Workforce: ~ 18,600 Company Working: Charles River Laboratories provides clinical testing and drug development services for vaccines, biosimilars, and medicines to treat several chronic diseases such as cardiovascular, skeletal, endocrine, central nervous system, cancer, and other diseases. It offers its services all around the world. The company operates through three segments, namely, Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (MS). The RMS segment sells research model strains and purpose-bred rats and mice for use by researchers. It also offers research models, genetically altered models & services, insourcing solutions, and research animal diagnostic services to help clients support the use of research models in research and screening of non-clinical drug candidates. The DSA segment provides early and in vivo discovery services, including toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, pharmacokinetics services, and safety assessment services, including toxicology, pathology, and safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics. In-vitro methods for conventional and quick quality control testing of sterile and non-sterile medicines and consumer products are provided by the manufacturing section. It operates in more than 20 countries, along with 90 sites around the globe.

Company Headquarters: Cambridge, US Founded: 2003 Workforce: ~51–200 Company Working: AVROBIO, Inc. (AVROBIO) is a phase two clinical-stage gene therapy company. The company’s Plato platform includes a proprietary vector system, automated cell manufacturing solution, and refined conditioning regimen with therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, US, and has offices in Toronto.

Company Headquarters: San Francisco, US Founded: 2013 Workforce: ~500 Company Working: Audentes Therapeutics (Audentes) is a clinical-stage biotechnology company. The company is involved in developing adeno-associated virus-based (AAV) genetic medicines. Audentes is developing AT132, used for the treatment of X-linked myotubular myopathy; AT845, for the treatment of Pompe disease; AT342 to treat Crigler-Najjar syndrome; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CPVT), and is involved developing vector-based antisense treatments for the treatment of myotonic dystrophy.

Company Headquarters: Cranbury, US Workforce: ~1,000 Founded: 2002 Company Working:Amicus Therapeutics, Inc (Amicus) is an international, patient-dedicated biotechnology company that develops and delivers innovative, high-quality medications for patients living with rare metabolic diseases. Amicus expanded its business in 27 countries across the globe with headquarters in Cranbury, US. The company’s international offices are located in Canada, Germany, France, Australia, Japan, Italy, the Netherlands, and Spain.

Company Headquarters: California, US Founded: 1997 Workforce: ~: 2,400+ Company Working: NuVasive, Inc. (NuVasive) is a leading medical device company in the global spine surgery market, focused on developing minimally disruptive surgical products and procedurally integrated solutions for spine surgery. The company’s currently marketed product portfolio is focused on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company’s procedurally integrated solutions use innovative, technological advancements, and a minimally disruptive surgical platform called Maximum Access Surgery (MAS), to provide surgical efficiency, operative reliability, and procedural versatility. Its international headquarter is located in Amsterdam, Netherlands.

Company Headquarters: Dublin, Ireland Founded: 1949 Workforce: ~91,000 Company Working: Medtronic plc (Medtronic) is a global healthcare solutions company that focuses on improving the lives of people through medical technologies, solutions, and services. The company with Covidien has accelerated and advanced its abilities to create meaningful innovations for hospitals, health systems, and healthcare providers. The company’s businesses majorly fall into four groups: the Cardiac and Vascular Group (CVG), the Restorative Therapies Group (RTG), the Diabetes Group, and the Minimally Invasive Therapies Group (MITG). Medtronic operates from over 370 locations in almost 160 countries. The company has been at the forefront of the cardiac telemedicine industry with patented technologies such as ambulatory devices with unified analysis & reporting software and on-site diagnostic systems. The company is committed to advancing science in patient monitoring. The company is awarded more than 4,600 patents.

Company Headquarters: Pennsylvania, US Founded: 1985 Workforce: ~830+ Company Working: Exactech, Inc. (Exactech) develops and produces innovative bone and joint restoration products that help surgeons worldwide make patients more mobile. Exactech distributes its products in more than 30 markets. The company has engineering innovative solutions for knee, hip, extremities, foot and ankle, and advanced surgical technologies. The company develops and produces innovative implants, instrumentation, and computer-assisted technologies for joint replacement surgery as well as biologic materials and bone cement systems. It has products that are distributed throughout the US and in 35+ markets in Europe, Latin America, Asia, and the Pacific.

Company Headquarters: Massachusetts, US Founded: 1895 Workforce: 18,000 + Company Working: DePuy Synthes is a subsidiary of Johnson & Johnson Services, Inc. The company is involved in manufacturing and marketing of orthopedic and neurological devices. It operates through business segments including joint reconstruction, trauma, spine, sports medicine, neuro, cranio-maxillofacial, power tools, and biomaterials. Additionally, it is engaged in manufacturing of reconstruction solutions for hip, knee, and shoulder replacement and trauma devices for internal and external fixation, implants, and instruments. It is directly present in more than 60 countries and operates in all major markets.

Company Headquarters: California, US Founded: 1990 Workforce: ~195 Company Working: Alphatech Holdings, Inc. (Alphatech) is a medical technology company that focuses on the design, development, and advancement of technology for better surgical treatment of spinal disorders. The company, through its subsidiary, Alphatec Spine, Inc., provides spine surgery solutions. It has a broad product portfolio designed to address the majority of the US market for fusion-based spinal disorder solutions. The company markets and sells its products in the US through a network of independent distributors and direct sales representatives. It partners with new and existing distributors to create a more dedicated and loyal sales channel for the future. It also plans to add new eminent distributors to expand future growth.

Company Headquarters: Laval, Canada Founded: 1959 Workforce: ~21,700 Company Working: Bausch Health Companies Inc. (Bausch Health) is one of the leading multinational specialty pharmaceutical company. The company develops, manufactures, and markets products for therapeutic areas such as gastroenterology (GI), dermatology, and eye health. It provides a broad range of over-the-counter (OTC) products, generic and branded generic pharmaceuticals, medical device, and branded pharmaceuticals. It was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. effective from July 2018. Bausch Health Companies Inc. provides its dermatology products through its segment named Ortho Dermatologics.

Company Headquarters: Lewisville, Texas, US Founded: 1980 Workforce: ~954 Company Working: Orthofix Holdings, Inc. (Orthofix) is a company that manufactures medical devices. It focuses on musculoskeletal therapies and products. The company operates through four operating segments, namely, bone growth therapies, spinal implants, biologics, and Orthofix extremities. The products manufactured and marketed by the company include devices that enhance bone fusion (bone growth therapies segment), implants used in spine surgeries (spinal implants segment), regenerative products and different forms of tissues to treat orthopedic and spinal conditions (biologics), and products to treat orthopedic conditions not related to the spine (Orthofix extremities segment). Orthofix Holdings, Inc. distributes its products via sales distributors and representatives in over 70 countries.

Company Headquarters: France Founded: 2008 Workforce: ~200 Company Working: Global Bioenergies is a technology-driven company that develops processes to convert renewable resources into hydrocarbons through fermentation. The company primarily focuses on the conversion of sugar, crops, and agricultural and forestry waste into isobutene. It has four subsidiaries, namely, Global Bioenergies GmbH, Syngip, IBN-One SA, and IBN-Two. Global Bioenergies GmbH, based in Germany, builds and operates an industrial-scale demonstrator at its refinery and focuses on specialized engineering services in gas fermentation. Syngip was founded in 2014 and has developed a process for the conversion of gaseous carbon sources into various valuable chemical compounds such as light olefins and petrochemical molecules, including isobutene. IBN-One SA was a wholly owned subsidiary of Global Bioenergies but was converted into a 50/50 joint venture with Cristal Union in May 2015. The company has obtained a license from Global Bioenergies to operate an isobutene process plant producing 50,000 tonnes annually. IBN-Two is based in Germany and has been established as a vehicle for bringing together German industry players to raise financing for building and operating the first bio-sourced isobutene production facility in the country.

Evonik is Germany's second-largest listed chemicals group after BASF and one of Europe's broadest pure-play specialty chemicals companies, generating €14.1bn of sales and €1.87bn adjusted EBITDA in FY2025. Since April 2025 it has been organised into two operating segments — Custom Solutions (formulated, application-driven specialties for coatings, personal care, pharma, and industrial additives) and Advanced Technologies (scale- and technology-driven platforms in silica, hydrogen peroxide, high-performance polymers, crosslinkers and animal-nutrition amino acids) — plus an Infrastructure segment (SYNEQT site services, Oxeno C4 chemicals) earmarked for divestment. Its competitive identity rests on deep process know-how, integrated German Verbund sites (Marl, Wesseling, Rheinfelden, Essen, Hanau), and leadership positions in global niches (fumed silica, DL-methionine, PA12, pharma excipients/lipids). The investment case is a transformation story — €400m-plus cost reduction, portfolio pruning, deleveraging — now overlaid by a live takeover approach from BASF and a near-majority foundation shareholder whose stance is pivotal. --- ### Company self-description Evonik describes itself as a global chemical company that goes "beyond chemistry" by combining innovative strength with leading technological expertise, providing customers with a competitive advantage through tailor-made products and solutions — positioning itself as a "superforce for industry" (company boilerplate, press releases 2026; Company Factbook 2026). Its stated strategic pillars (Capital Markets Day, 22 May 2025) are: a differentiated portfolio in two segments, sustainable innovation, a balanced regional footprint (ambition of roughly one-third of sales in each of Americas, EMEA and Asia-Pacific), and a performance culture. ### Independent characterisation Evonik is a mid-cap, diversified specialty and "semi-specialty" chemicals manufacturer. Roughly 80% of FY2025 sales (€11.5bn of €14.1bn) came from the two core segments; the remaining ~18–19% came from Infrastructure & Other, which bundles low-margin site services and the cyclical C4 (Oxeno) petrochemical chain. The business is overwhelmingly a product business (manufactured chemicals sold B2B under supply contracts, frame agreements and spot), with smaller service/contract components: (i) pharma CDMO and contract manufacturing (Health Care — lipids/LNPs, drug substances, oral drug delivery), (ii) site infrastructure and utility services sold by SYNEQT to ~two dozen third-party companies in the Marl and Wesseling chemical parks, and (iii) licensing/technology (e.g., HPPO hydrogen peroxide technology with partners; catalysts). Subscription revenue is negligible. Precise revenue-model split (product vs service vs licensing) is n/d. ### Value-chain position Evonik sits mid-stream: it buys petrochemical feedstocks (C4 raffinate, propylene, methanol, ammonia, natural gas/energy, silicon metal, sulphur) and converts them into intermediates and formulated specialties sold to formulators and OEMs. Upstream integration is partial (own C4 cracking downstream of refinery/cracker streams at Marl and Antwerp; own HCN and methionine chain in Antwerp, Mobile and Singapore). Downstream, it rarely sells to consumers; its products are ingredients typically <5% of the customer's cost but critical to performance ("small cost share, high value-in-use"), which supports pricing power in the specialty businesses. ### Customer types and end markets Customers include paint and coatings formulators, adhesives and sealants makers, tyre and rubber producers (silica/silanes), cosmetic and household-care brands, pharmaceutical and biotech companies (excipients, lipids, CDMO), animal-feed mills and integrators (methionine), plastics and automotive suppliers (PA12, PEEK), aerospace (ROHACELL foams), pulp & paper, electronics and semiconductors (high-purity silanes/chlorosilanes, H2O2), renewable energy and hydrogen (membranes, catalysts), and biodiesel producers (alkoxide catalysts). End-market exposure is broad: consumer/personal care, health care, food/feed, automotive and mobility, construction, coatings, industrial, energy/agriculture. A precise end-market % split for FY2025 is n/d in sources reviewed.

ExxonMobil is the largest investor-owned integrated energy and petrochemical company in the Western world by market value, earnings and cash flow. In 2025 it produced 4.7 million oil-equivalent barrels per day (the highest level in more than 40 years) and ran about 4.0 million barrels per day of refinery throughput. It is also one of the world's largest makers of polyolefins and synthetic lubricants (Mobil 1). The strategy rests on four ideas: - concentrating capital in low-cost-of-supply "advantaged" assets: the Permian Basin, Guyana's Stabroek block, and LNG; - integrating Upstream with Product Solutions (refining, chemicals, specialty products); - deploying proprietary technology; - pursuing structural cost reduction ($15.1 billion cumulative savings by end-2025 versus 2019, rising to $16.3 billion by mid-2026). It has an AA-category balance sheet and has raised its dividend for 43 consecutive years. In 2025 it returned $37.2 billion to shareholders. Its December 2025 plan targets $25 billion of earnings growth by 2030 versus 2024 at constant prices. Its Low Carbon Solutions business (CCS, hydrogen, lithium, carbon materials) is a long-dated optionality platform rather than a core earnings driver. --- **Company's own description (10-K FY2025, Item 1, paraphrased).** ExxonMobil says its principal business covers four activities: - exploring for and producing crude oil and natural gas; - manufacturing, trading, transporting and selling crude oil, natural gas, petroleum products, petrochemicals and a broad range of specialty products; - pursuing lower-emission and other new businesses, including carbon capture and storage, hydrogen and ammonia, lower-emission fuels, Proxxima™ resin systems, carbon materials, low-carbon data centers and lithium; - supporting all of these with extensive research. The company says it held more than 8,000 active patents worldwide at end-2025. It adds that no business segment's profitability depends on any single patent, trademark, licence or concession. **Organisational model.** Since 2022 the company has been run as three business lines: - **Upstream**, through ExxonMobil Upstream Company; **Product Solutions:** (Energy, Chemical and Specialty Products); **Low Carbon Solutions (LCS):** These are supported by centralised service companies. ExxonMobil Global Operations (from 1 January 2026) brings together operations for all three businesses. Other service companies are Global Projects Company, Global Business Solutions, Supply Chain, and Technology & Engineering. External financial reporting uses four segments: Upstream, Energy Products, Chemical Products and Specialty Products, plus Corporate & Financing. (Source: 10-K FY2025; Nov 2025 leadership release.) **Business and revenue model.** ExxonMobil earns almost all of its revenue from product sales: crude, natural gas and LNG, refined fuels, petrochemicals, lubricants and specialty products. These are priced off commodity benchmarks plus differentials. Services, subscriptions and licensing are immaterial to revenue; technology licensing exists but is not separately disclosed. **Value-chain position.** ExxonMobil spans the full hydrocarbon chain: - exploration and production (upstream); - midstream logistics, including pipelines, Golden Pass LNG and the Denbury CO2 pipeline network; - refining, the largest refining footprint of any IOC with about 4.1 Mb/d of capacity; - base chemicals and polymers; - specialty products such as lubricants, resins and synthetics; - branded retail, mainly through third-party branded wholesalers. Most retail sites in its main markets are owned by dealers or distributors rather than the company. **Customer types:** - refiners and traders (crude and NGLs); - utilities and LNG buyers (gas and LNG); - branded wholesalers, airlines, shipping lines and industrial users (fuels); - converters and packaging, automotive, construction and consumer-goods manufacturers (chemicals); - OEMs, fleets, industrial plants and DIY consumers (lubricants); - heavy industrial emitters (CCS customers such as CF Industries, Linde, Nucor and Calpine, per company announcements). **End-markets served:** transportation fuels; power generation and heating; industrial energy; petrochemical feedstocks; packaging; automotive; construction; agriculture (fertiliser via CCS customers); consumer goods; aviation; marine; and emerging markets in battery materials (lithium, synthetic graphite) and data-center power. **Independent characterisation.** ExxonMobil remains a hydrocarbon "super-integrator" whose earnings are about 70% leveraged to upstream liquids prices. Upstream contributed $21.4 billion of FY2025 segment earnings before Corporate & Financing, about 66% of the $32.4 billion segment total. Two structural shifts since 2019 are changing the earnings profile: **Upstream mix shift to advantaged barrels:** Permian, Guyana and LNG made up 59% of 2025 production, up about 7 percentage points in a year (4Q25 release). **Product Solutions mix shift to "high-value products":** Performance chemicals, performance lubricants and lower-emission fuels are projected to exceed 40% of Product Solutions earnings by 2030 (Corporate Plan, Dec 2025). The company's competitive edge is mostly cost and integration rather than technology licensing. The 2026 Middle East conflict showed that about 20% of production sits in a geopolitically exposed region with much lower earnings weight.

Company Headquarters: Japan Founded: 1935 Workforce: ~31,837 Company Working: Sumitomo Chemical Co., Ltd (Sumitomo Chemical) is one of the leading chemical companies in Japan. It is engaged in the manufacturing and sale of various chemical products. The company operates through petrochemicals and plastics, energy and functional materials, IT-related chemicals, health and crop sciences, and pharmaceuticals segments. Under the petrochemicals and plastics segment, it manufactures ammonium sulfate that is used as an industrial chemical. The Sumitomo Group comprises over 100 subsidiaries and has a significant presence in the Asian market. Sumitomo Chemical’s research organization comprises three major laboratories—the business sector research laboratories, corporate research laboratories, and production and safety fundamental technology center.

Company Headquarters: Netherlands Founded: 2007 Workforce: ~13000 Company Working: LyondellBasell Industries Holdings BV (LyondellBasell) is the foremost plastics, chemicals, and refining company in the world. It manufactures materials and products that are key solutions to modern challenges such as enhancing food safety through lightweight and flexible packaging, water purity protection through stronger and versatile pipes, and improving the safety, comfort, and fuel efficiency of automobiles. The company’s operating segments are olefins and polyolefins, intermediates and derivatives, refining, and technology. It is also the world’s largest global licensor of polyolefin technologies and a leading producer of high purity isobutylene.